Global Stem Cells’ group affiliate Adimarket set to launch new products during the international event.
MIAMI LAKES, Florida—The International Society for Stem Cell Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, will host a two-day medical congress in Cancun, Mexico. The 7 Congreso Internacional de Terapias Avanzadas en Medicina will take place on December 7-8, 2019 and will feature speakers from various countries, including the United States, Argentina, Mexico, and Colombia.
Congress organizers expect over 250 Mexican doctors will attend the event, which will feature a variety of experts in the field of regenerative medicine and cutting-edge products in the industry that are designed to help treat patients suffering from degenerative diseases.
Adimarket, the largest online regenerative medicine store and a subsidiary of the Global Stem Cells Group, will be on hand to launch its newest allogeneic stem cells products during the event. These heterologous compounds were developed exclusively for a LATAM market, striking a balance between a high-quality treatment option and an affordable price. Products currently offered by Adimarket in this category include exosomes, cord blood derived stem cells, and stem cells derived from amniotic fluid.
All of Adimarket’s products are designed to help provide safe and effective treatment options to doctors treating patients suffering from degenerative diseases.
To learn more about Adimarket and all of its regenerative medicine solutions, visit https://www.adimarket.net/. To learn more about ISSCA and all of their upcoming and past events, visit https://issca.us/.
The ongoing partnership will offer certification in regenerative medicine for European-based medical practitioners .
MIAMI LAKES, Florida—The International Society for Stem Cell Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, has signed an agreement with European-based Clinica Planas to offer a stem cells certification training program. The first event will be held in Barcelona on October 18-19, 2019.
“The Global Stem Cells Group is pleased to partner with Clinica Planas to offer this important certification in cell therapies,” said Benito Novas, Vice President of the Global Stem Cells Group. “This partnership will continue our mission to help provide knowledge of regenerative medicine practices and treatment options to physicians across the globe.”
Clinica Planas has two locations in Spain—Barcelona and Madrid—and is known as one of the most prestigious medical centers in Europe. In this new deal, Clinical Planas will partner with the Global Stem Cells Group to help train European-based physicians in the regenerative medicine industry’s best practices and most up-to-date knowledge.
The inaugural certification workshop will be held on October 11-12 in Barcelona, with additional certification opportunities to be offered on an ongoing basis in the future. During the two-day event, physicians will receive insight on 22 proprietary treatment protocols to treat degenerative diseases, acquire skills to be able to offer alternative treatment options to patients who have yet to try regenerative medicine as an option, and join an exclusive network of doctors at the forefront of medical science.
“Our goal is to help physicians looking for new treatment options for their patients suffering from degenerative diseases gain the necessary skills to be able to offer regenerative treatments as an option to alleviate their patients’ suffering,” Novas noted.
To learn more about the October 2019 certification event in Barcelona, visit http://cursocelulasmadre.com/entrenamiento-en-barcelona/.
MIAMI LAKES, FL, May 30, 2019-Global Stem Cells Group Inc. (GSCG) is pleased to announce that it has entered into a binding letter of intent to sell 100% to Lans Holdings Inc. (OTCPink: LAHO)
GSCG operates in the global stem cell market which is forecasted by Transparency Market Research to reach $270 billion dollars by 2025 of which roughly 40% or $100 billion will be derived from outside of North America and growing at a 13.8% compounded annual growth rate.
GSCG specializes in leading-edge stem cell research, patient application and physician training. The company licenses its name and intellectual property to physicians around the world and supplies them with necessary equipment and medical supplies to perform stem cell treatments. The company currently has one of the largest member clinic networks in the world spanning over 25 countries.
“We are very pleased to have entered into this binding LOI with Global Stem Cells Group,” said Dave Christensen, CEO of Lans Holdings Inc. “This transaction represents a significant opportunity for our company to enter the explosive field of Stem Cell technology with a proven and seasoned team and I look forward to working closely with GSCG to execute on their growth plans.”
“We are excited to join forces with Lans Holdings,” said Benito Novas, President and CEO of Global Stem Cells Group. “This union will allow us to have access to the capital markets to further fuel our growth as the global stem cells market enters into an accelerated expansion phase.”
Novas is a global expert on medical practice marketing strategies, specifically those pertaining to regenerative medicine.
MIAMI LAKES, Florida—Benito Novas, CEO of the Global Stem Cells Group, will serve as the keynote speaker at an event sponsored by the International Society for Stem Cell Application held in Mexico City on May 3-4, 2019. Novas is known as a global experts on medical practice marketing strategies, specifically those pertaining to the regenerative medicine field.
The Mexico City Stem Cells Seminar is a two-day medical congress and the first of its kind to offer an entire day focused on medical marketing. Novas will serve as both a keynote speaker and also as a marketing professional to offer his expertise during this portion of the congress.
As the CEO of the Global Stem Cells Group, Benito Novas is an entrepreneur and leader of an international enterprise that provides complete services to the regenerative medicine industry. Though his work, he has created programs that provide Stem Cells Certification opportunities for practitioners in the field in addition to supporting stem cells medical research efforts across the globe.
Benito Novas is known as a global expert on research marketing strategies, especially pertaining to the realm of regenerative medicine. He has extensively researched marketing strategies that are proven to grow medical practices worldwide, including those in the US. Putting his research to use, Novas has successfully grown regenerative medical practices across the globe.
In addition to his personal research pursuits, Benito Novas frequently lends his expertise as a marketing expert to private medical practices and other groups worldwide. He has also conducted medical business in various countries across South America and the Middle East.
To learn more about Benito Novas, visit his LinkedIn profile at https://bit.ly/2IMgGtJ.
Cancun Stem Cells Center Offers Hope for US Patients Suffering from Degenerative or Chronic Diseases
Free from US regulatory constraints, the center offers stem cells protocols needed to effectively treat a wide variety of disease.
MIAMI LAKES, Florida—For physicians based in the United States looking for high-quality patient care in the realm of regenerative medicine, the Stem Cells Center in Cancun, Mexico offers a cutting-edge care solution outside of the US. The Cancun center is a member of the Global Stem Cells Group network, which is comprised of a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology and regenerative medicine.
A number of conditions that patients present may require physicians to use treatment methods that will increase the cell counts that are delivered during the protocol. For patients suffering from chronic degenerative conditions or disorders based in genetics, physicians may need to culture expanded autologous cells. Currently, autologous stem cell expansion conducted in labs before being reintroduced into patients is not a viable treatment option in the US due to regulatory constraints. Thus, both the patient and physician are left turning to less effective treatment options using only cells obtained in the medical office.
For patients suffering from some degenerative conditions, more involved methods of therapy and more aggressive ways of deploying cells may be necessary than current US regulations allow. To deploy these more aggressive forms of treatment, catheterization is ideal. To perform intricate catheterizations of the carotid artery and the vascular arteries of the brain, for instance, it is critical to have a properly staffed and equipped hospital to perform the procedure. A hemodynamics suite and having an intensive care unit nearby are essential tenets of such treatment protocols.
Patients requiring more aggressive and effective treatment options for degenerative and chronic diseases can receive the treatment they need at the Stem Cell Center in Cancun. Because the facility is located outside of the US, patients and physicians are not bound by regulatory limitations affecting lab-expanded autologous cells.
The Global Stem Cells Groups’ facility in Cancun is a Level 3 hospital equipped with an intensive care operating room and a hemodynamics suite ideal for patients needing critical treatments using regenerative medicine. Hospital staff includes a highly-ranked, high-level specialist in the area of regenerative medicine. Current facility protocols are in place to cater to patients needing the facility’s specialized services, and the hospital is associated with a local laboratory that can easily provide the amount of allogeneic cells needed for treatments requiring them.
Physicians with patients who may benefit from the medical services offered at the Stem Cells Center in Cancun are invited to reach out to set up a meeting to learn more about what services the facility offers and how to access the center for treatment. To learn more about the Global Stem Cells Group and the Cancun facility, visit http://www.stemcellsgroup.com/.
AdimarketTM Flow uses exosomes in compliance with US regulations to provide innovative treatment options to those suffering from degenerative diseases.
MIAMI LAKES, Florida—Adimarket, LLC, a subsidiary of the Global Stem Cells Group is a leading distributor of products for regenerative medicine providers, has announced a new stem cells product, exosomes, to its product portfolio. The product is available online via Adimarket’s website at https://www.adimarket.net/ and comes in a 1 mL vial and is available for 24-hour delivery after orders placed from any US city.
Exosomes contain a variety of genetic materials, such as mRNAs and microRNAs (miRNAs), which imply they may play a critical role in cell-to-cell communication. AdimarketTM Flow is procured and processed according to US standards and regulations established by the American Association of Tissue Banks (AATB) and the United States Food and Drug Association (FDA).
Exosomes are currently non-reactive and FDA approved.
Exosomes provide an exciting new treatment option for those suffering from degenerative diseases. As a next-generation therapy option, exosomes work by isolating the beneficial signals released by stem cells and use them rather than the stem cells themselves. Using exosomes as a viable therapeutic option makes sense, as they cause other cells to react and change their behavior accordingly. Research and application demonstrate that there is incredible therapeutic potential within extracellular vesicles, particularly exosomes.
Physicians exploring exosomes as a therapeutic option should familiarize themselves with their components and signal deliveries. Components of exosomes include MSCs, cytokines, chemokines, growth factors and hyaluronic acid (HA). They are able to deliver the following signals to target cells: anti-apoptotic, anti-fibrotic, pro-angiogenic and pro-differentiation.
Adimarket, LLC is a leading distributor of products for practitioners in the regenerative medicine field. The online market offers a vast portfolio of goods, ranging from office equipment to cellular- and tissue-based products. The Global Stem Cells Group, which owns Adimarket, continually develops and launches new products specifically for regenerative medicine practitioners to assure physicians have all they need to practice in their field safely and effectively.
To learn more about AdimarketTM Flow and all of Adimarket’s regenerative medicine products, visit https://www.adimarket.net/product/cellgenic-flow-1ml-exosomes/.
The organization recognizes Cuban doctors living outside of Cuba committed to delivering high-quality care
MIAMI LAKES, Florida—Dra. Maritza Novas, MSc, has been earned the honorary distinction of being named as a member of the Asociacion de Medicos Cubanos Altamente Especializados, or AMECAE. The organization recognizes Cuban doctors living outside of Cuba who provide excellence in care and research in highly specialized medical fields.
AMECAE is a non-profit organization composed of Cuban doctors living outside of Cuba that has challenged the medical community to provide the highest quality of care to patients worldwide. Each year, AMECAE welcomes a distinguished new class of doctors into the organization who have demonstrated that they have provided great service to their patients while contributing to helping their respective medical specialties overcome challenges and reach new levels of success.
Dra. Novas currently serves as the Global Stem Cells Group’s (ISSCA) Development and Research Director. The group is a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine. During her time with ISSCA, Dra. Novas has developed new standards for the stem cells industry through establishing new regenerative medicine protocols. She also serves as the head of the Stem Cells Center in Cancun, which provides stem cells treatments for patients who travel from the US who suffer from degenerative diseases.
Dra. Novas earned AMECAE’s honor as a result of her vast impact on the field of regenerative medicine. In her time as a doctor, Dra. Novas has made a profound impact on her patients through innovative treatments using regenerative medicine. Additionally, in her role as both a physician and researcher, Dra. Novas has trained countless other doctors in the area of regenerative medicine, which has led to their certification in the area.
To learn more about the Global Stem Cells Group and the work Dra. Novas is engaged in, visit http://www.stemcellsgroup.com/.
The center in Chochabamba is a subsidiary of the Global Stem Cells Group and is the 35th such center in the world.
MIAMI LAKES, Florida—The Global Stem Cells Group, a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, is pleased to announce the opening of the Stem Cells Center in Chochabamba, Bolivia. Inaugural events celebrating the center’s opening will take place in Chochabamba on June 8-9, 2019.
The Bolivian center is the 35th Stem Cells Center in the world, strengthening the Global Stem Cells Group’s presence worldwide as they seek to expand research for and the practice of regenerative medicine across the globe.
Representatives from the Global Stem Cells Group and local physicians alike see the impending impact on the Bolivian medical community from having an innovative center such as the Stem Cells Center as a positive one. The center will offer a permanent space within the country where industry experts can train Bolivian doctors in the latest stem cell therapies. These training programs will result in better care for Bolivian patients suffering from degenerative conditions by keeping care close to home and introducing them to more effective treatment options.
The Global Stem Cells Group will provide the center with all necessary medical equipment to support a regenerative medicine practice. The group additionally provided training to all Bolivian doctors and support staff working at the center, which will be led by Dra. Cecilia Vargas.
As part of the two-day inaugural celebration, Global will be hosting a social at the Hotel Chochabamba on June 8th. The local medical community is welcome to join the event.
To learn more about the Global Stem Cells Group, visit http://www.stemcellsgroup.com/.
To learn more about the Stem Cells Center, visit https://www.youtube.com/watch?v=Q4ubnCSVpSs
ISSCA doctors to serve as keynote speakers at international conference and will host an additional stem cells course in Barcelona.
MIAMI LAKES, Florida— The International Society for Stem Cell Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, has accepted an invitation to speak at the XXVIIas Jornadas Mediterraneas de Confrontaciones Terapeuticas en Medicina y Cirugia Cosmetica in Barcelona. The conference will be held on May 23-25, 2019 at the Hotel Barceló Sants, with experts from ISSCA leading the keynote session on May 25th. Following the conference on May 26th,, ISCCA doctors will also be hosting a one-day stem cells course for practitioners of regenerative medicine.
Dra. Maritza Novas of the United States and Dr. Leopoldo Parada of Chile will be speaking on behalf of ISSCA about new therapies based on allogenic compounds such as amniotic liquid, Wharton’s jelly, cord blood, and exosomes and how they present exciting new treatment opportunities for those practicing regenerative medicine.
Drs. Novas and Parada will shed light on new advances in allogenic compound research and share details with regenerative medicine practitioners on how allogenic compounds are safe treatment options for their patients, as they must pass through rigorous quality control in labs before being shipped to medical offices. Additionally, independent tests show that allogenic compounds have better cellular counts than other biological matter. Doctors currently using allogenic compounds have also reported faster treatment times associated with allogenic protocols, citing a 15-minute turnaround time versus 2 hours required to obtain stem cells from their patients.
After completing their keynote talk at Jornadas Mediterraneas, Drs. Nova and Parada will be leading a one-day stem cells seminar to discuss in further detail allogenic compound clinical applications and the latest clinical trials. The seminar will wrap up with a live patient demonstration.
ISSCA has attended Jornadas Mediterraneas for the last six years. It is a premier conference in the medical community attracting more than 500 doctors from across the globe each year.
To learn more about ISSCA and all of their upcoming and past events, visit https://issca.us/.
ISSCA’s training programs assist physicians and researchers in developing better protocols for stem cell treatments.
MIAMI LAKES, Florida— The International Society for Stem Cell Application, a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, is continuing to expand its global training efforts by sponsoring three upcoming training sessions over the next month. The group has a busy schedule, with trainings taking place in Amsterdam, Abu Dhabi, Atlanta, Bogota, Miami and Mexico City.
ISSCA instructors will be hosting two onsite trainings, one in Amsterdam, Netherlands on February 22-23 and another in Abu Dhabi, United Arab Emirates on March 2-3. The training is designed to assist physicians interested in introducing regenerative medicine into their practices adhere to industry practices. Physicians will learn about industry developments and the latest advances in cellular-based treatment protocols.
Utilizing ISSCA’s over 10 years of experience in regenerative medicine, the onsite trainings seek to bring the latest advances in the field to physicians across the world, removing barriers to access. In addition to training physicians, the group uses hands-on-training methods to instruct other medical staff in cellular treatment protocols so they can effectively assist their tending physicians. Trainings are highly personalized and offer physicians the ability to learn only the regenerative medicine treatments they are most interested in.
In early March, ISSCA instructors will also be traveling to Atlanta, Georgia to train physicians on allogenic compound stem cells derived from cord blood. This two-day training will take place in on March 29-30. Physicians with an interest in new regenerative medicine breakthroughs that have produced safer and shorter recovery times and those that have led to higher cellular counts in the degenerative disease treatment process will find this training of interest.
Instructors will lead physicians through a deep dive into the latest stem cell advances pertaining to cord blood research. Attendees will learn about processes for how to extract stem cells from a healthy donor and protocols on how to process stem cells in the lab while adhering to the highest quality control standards.
Instructors will additionally share the science behind allogenic compounds derived from cord blood and which current protocols use cord blood derived stem cells to promote patient healing.
ISSCA trainers will be rounding out their upcoming training schedule with visits to Bogota, Colombia on March 15-16, Miami, Florida on March 22-23 and Mexico City, Mexico on March 29-30. These three trainings will offer Stem Cell Training Certification for physicians seeking to expand their knowledge on the newest stem cells protocols for those wanting to integrate regenerative medicine into their practices. The protocols covered in the trainings can be implemented in medical offices with mini lab equipment. The instructors will engage physicians in hands-on instruction where doctors can practice on live patients.
Trainings in Bogota and Mexico City will be conducted in Spanish, and interested participants can find more information at www.cursocelulasmadre.com, while interested Miami participants can learn more at https://www.stemcelltraining.net/hands-on-course.
To learn more about ISSCA, visit https://www.issca.us/